Galectin Therapeutics reported $27.29M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Gilead Sciences USD 18.64B 1.25B Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Merck USD 35.02B 8.5B Mar/2026